SCHEMBL1009577

SCHEMBL1009577

N#Cc1ccccc1Oc1cn[nH]c(=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
GAA P10253 1/20 0.48
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
LRRK2 Q5S007 1/20 0.45
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPK14 Q16539 3/20 0.39
CYP19A1 P11511 1/20 0.39
AR P10275 1/20 0.39
KCNH2 Q12809 1/20 0.39
CYP3A4 P08684 1/20 0.39
PIN1 Q13526 1/20 0.38
TRPA1 O75762 1/20 0.38
SCN9A Q15858 1/20 0.38
DHODH Q02127 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008641 0.78 PRMT5 (0.43) POLBPRMT5WDR77ALDH1A1AR
SCHEMBL6216924 0.77 POLB (0.54) POLBGAAPRMT5WDR77LRRK2
SCHEMBL5409340 0.75 TRPA1 (0.58) POLBGAALRRK2PDE4APDE4B
SCHEMBL1009006 0.75 LTA4H (0.44) PRMT5WDR77
SCHEMBL1009652 0.74 TRPA1 (0.40) PDE4BCYP3A4TRPA1
SCHEMBL1010609 0.73 PIN1 (0.43) POLBGAAPRMT5WDR77LRRK2
SCHEMBL1008229 0.73 CTNNB1 (0.56) GAALRRK2ALDH1A1SMN1; SMN2CYP3A4
SCHEMBL1010645 0.73 LMNA (0.40) GAAALDH1A1SMN1; SMN2
SCHEMBL1009349 0.72 ALDH1A1 (0.42) PRMT5WDR77ALDH1A1
SCHEMBL1162713 0.70 GAA (0.72) POLBGAALRRK2PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK POLB 2078/4885GAA 83/4885PRMT5 2683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.